International Congress for Lung Cancer and Head & Neck Cancer 2011

Key Topics

• Personalized maintenance therapy in lung cancer
• Lung cancer patients selection for personalized chemotherapy
• Adjuvant and neoadjuvant therapy in early stage lung cancer
• Patients education on the personalized and optimized multimodality therapy in the treatment of lung cancer
• Clinical data supporting the optimal use of EGFR TKI`s in the treatment of lung cancer based on biomarkers leading to change in practice
• Patient selection for integration of bevacizumab in the management of lung cancer
• HDAC inhibitors/ talactoferrin/STA 9090 and other HSP 90, c-met inhibitors, EGFL-7, ARQ197, farletuzumab/Hedge-Hog inhibitors that potentially improve upon standard chemotherapy and linifanib
• Managing primary and secondary resistance to anti-EGFR therapy in patients with lung cancer
• Symptom control and management of toxicities associated with chemotherapy and targeted agents
• Novel treatment strategies for small cell lung cancer
• Supportive cancer care in the era of targeted therapy

Who should Attend

Radiation oncologists, primarily to medical oncologists, registered nurses, pharmacists, nurse practitioners interested in new developments for treatment of lung cancer and head & neck cancer and physician assistants.